2017
Corrigendum re: “Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications” [Eur Urol 2017;71:55–65]
Gershman B, Van Houten HK, Herrin J, Moreira DM, Kim SP, Shah ND, Karnes RJ. Corrigendum re: “Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications” [Eur Urol 2017;71:55–65]. European Urology 2017, 71: e160. PMID: 28118942, DOI: 10.1016/j.eururo.2017.01.022.Peer-Reviewed Original Research
2016
Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications
Gershman B, Van Houten HK, Herrin J, Moreira DM, Kim SP, Shah ND, Karnes RJ. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications. European Urology 2016, 71: 55-65. PMID: 26995328, DOI: 10.1016/j.eururo.2016.03.015.Peer-Reviewed Original ResearchConceptsRate of biopsyProstate-specific antigen (PSA) screeningPredictors of complicationsPostbiopsy complicationsUSPSTF recommendationsAntigen screeningProstate biopsyRelative morbidityScreening TrialUS Preventive Services Task Force (USPSTF) recommendationOvarian Cancer Screening TrialAmerican Urological Association guidelinesMorbidity of biopsyPrior fluoroquinolone useEuropean Randomized StudyCancer Screening TrialInterrupted time series analysisProportion of menTask Force recommendationsInfectious complicationsAnticoagulant useComplication rateUnderwent biopsyRandomized studyScreening guidelines